Net income grew 54% to $2.0 billion in Q1 2026.
Acquired Arcellx and Ouro Medicines to expand oncology and immunology portfolios.
Product gross margin increased by 249 basis points to 79.2%.
Anticipated $11.5 billion IPR&D charge to cause a net loss in Q2 and full year 2026.
The Q1 filing presents a company at a crossroads, balancing immediate operational strength against long-term structural risks. On one hand, Gilead's ability to grow its HIV and oncology revenues while expanding gross margins suggests a high level of commercial execution. The strategic acquisitions of Arcellx and Ouro Medicines indicate a clear vision to diversify away from virology, potentially transforming the company's risk profile over the next three to five years. However, the sheer scale of the upcoming $11.5 billion R&D charge and the persistent debt load create a volatile backdrop for shareholders. The tension between the company's aggressive capital return program—including billions in buybacks and dividends—and its massive M&A spend suggests a tightrope walk regarding liquidity. Ultimately, the stock's trajectory will depend on whether the new oncology and immunology assets can offset the inevitable pricing erosion of the HIV portfolio and the collapse of the pandemic-era revenue streams.